Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Bibliographic Details
Main Authors: Molife, L Rhoda, Yan, Li, Vitfell-Rasmussen, Joanna, Zernhelt, Adriane M, Sullivan, Daniel M, Cassier, Philippe A, Chen, Eric, Biondo, Andrea, Tetteh, Ernestina, Siu, Lillian L, Patnaik, Amita, Papadopoulos, Kyriakos P, de Bono, Johann S, Tolcher, Anthony W, Minton, Susan
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884022/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884022/

Similar Items